Anti-neoplastic Effect of Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid on U937 Acute Myeloid Leukemia Cell Line

LAUR Repository

Show simple item record

dc.contributor.author Babikian, Patil
dc.date.accessioned 2022-07-20T09:44:35Z
dc.date.available 2022-07-20T09:44:35Z
dc.date.copyright 2020 en_US
dc.date.issued 2020-05-05
dc.identifier.uri http://hdl.handle.net/10725/13843
dc.description.abstract Acute myeloid leukemia is a heterogeneous malignant disorder characterized by rapid buildup of abnormal myeloid blasts in the blood and the bone marrow. This uncontrolled accumulation eventually interferes with the normal functioning of healthy blasts. Despite major advances in AML research, high incidence and death rates persist. Recently the role of epigenetic modifications in leukemogenesis has been well acknowledged, including histone deacetylation and DNA methylation, which frequently target the promoters of key genes involved in pathways such as apoptosis and cell cycle. Several studies have reported that combining different epigenetic modulators significantly boosts the effects of each one when used individually. In this study, the effects of a histone deacetylase inhibitor and a DNA methyl transferase inhibitor, suberoylanilide hydroxamic acid and Decitabine, respectively, were evaluated using U937 cells as an AML model cell line. Once having determined their growth inhibitory effects, and cell cycle arresting and apoptotic powers, two strategies of combining SAHA and DAC were assessed: simultaneous and sequential treatments. The sequential combination treatment, which consisted of priming the cells with DAC and then adding SAHA, was shown to enhance the effects of each epigenetic modulator, unlike the simultaneous treatment strategy. The effects were observed for growth inhibition, apoptosis stimulation and cell cycle arrest. Lastly, the changes incurred upon the sequential treatment were evaluated at the level of protein expression. The results revealed that, relative to controls and cells treated with only one drug, both intrinsic and extrinsic apoptotic pathways were activated by the sequential combination of SAHA and DAC. Further studies should be conducted to decipher the complete molecular mechanisms and pathways involved in the growth inhibitory effects of the combined SAHA and DAC treatment. en_US
dc.language.iso en en_US
dc.subject Acute myeloid leukemia -- Treatment en_US
dc.subject Epigenetics -- Methodology en_US
dc.subject DNA -- Methylation en_US
dc.subject Cancer -- Molecular aspects en_US
dc.subject Lebanese American University -- Dissertations en_US
dc.subject Dissertations, Academic en_US
dc.title Anti-neoplastic Effect of Adjuvant Epigenetic Therapy of Decitabine and Suberoylanilide Hydroxamic Acid on U937 Acute Myeloid Leukemia Cell Line en_US
dc.type Thesis en_US
dc.term.submitted Spring en_US
dc.author.degree MS in Molecular Biology en_US
dc.author.school SAS en_US
dc.author.idnumber 201301352 en_US
dc.author.commembers Daher, Costantine
dc.author.commembers Nawas, Tarek
dc.author.department Natural Sciences en_US
dc.description.physdesc 1 online resource (xx, 120 leaves): ill. (some col.) en_US
dc.author.advisor Rizk, Sandra
dc.keywords Acute myeloid leukemia en_US
dc.keywords Suberoylanilide hydroxamic acid en_US
dc.keywords Decitabine en_US
dc.keywords epigenetics en_US
dc.keywords combination therapy en_US
dc.description.bibliographiccitations Bibliography: leaf 93-120. en_US
dc.identifier.doi https://doi.org/10.26756/th.2022.369
dc.author.email patil.babikian@lau.edu.lb en_US
dc.identifier.tou http://libraries.lau.edu.lb/research/laur/terms-of-use/thesis.php en_US
dc.publisher.institution Lebanese American University en_US
dc.author.affiliation Lebanese American University en_US

Files in this item

This item appears in the following Collection(s)

Show simple item record

Search LAUR

Advanced Search


My Account